Condition
Bile Duct Adenocarcinoma
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (2)
P 4 (1)
Trial Status
Unknown2
Recruiting1
Withdrawn1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07120295Phase 4RecruitingPrimary
Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories
NCT06092645Phase 2UnknownPrimary
Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma
NCT04042831Phase 2UnknownPrimary
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
NCT03117855Phase 1WithdrawnPrimary
Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery
Showing all 4 trials